Idiopathic pulmonary fibrosis (IPF) is a progressive disease with an unknown cause. Two
drugs, nintedanib and pirfenidone, have been shown to slow, but not stop, disease progression…

… Contributors: Nathan Hambly was involved in conception and design of the review, …
Competing interests: Nathan Hambly has received consultancy honoraria from Actelion …

In severe refractory asthma, both an understanding of the underlying pathophysiologic
mechanisms driving airway inflammation and the identification of appropriate biomarkers in …

Background. The relative rarity and diversity of fibrotic interstitial lung disease (ILD) have
made it challenging to study these diseases in single-centre cohorts. Here we describe …

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex
cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk …

Background Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by
progressive physiological, symptomatic and/or radiographic worsening. The real-world …

Background and objective Inhalational exposures are a known cause of interstitial lung
disease (ILD), but little is understood about their prevalence across ILD subtypes and their …

… Fisher MD g , Nathan Hambly MD h , Martin Kolb MD h , Julie Morisset MD i , Shane
Shapera MD g , Christopher J. Ryerson MD a b … SD Nathan, U. Costabel, C. Albera, et al. …

Rationale: Early access to subspecialty care is associated with improved outcomes for patients
with fibrotic interstitial lung disease (ILD). Access to ILD care may be limited for patients …

Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor
necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis. …